EpiVario is a preclinical-stage drug discovery and development company targeting memory-related psychiatric disorders, including PTSD, alcohol and drug addiction, and Alzheimer's disease. Its core approach targets memory formation and reconsolidation, administering drugs in conjunction with psychotherapy to disassociate stress linked to traumatic memories. The company signed an option agreement with the University of Pennsylvania for an epigenetic marker featured in a Nature Genetics study that could be targeted for early-stage Alzheimer's therapy. Over the next year EpiVario will seek to identify modulators that could limit activity of epigenetic regulators to prevent Alzheimer's disease. EpiVario closed a Seed Funding round with a new investment of $112,500, bringing total outside investment to $717,000; the additional funds will be used to advance addiction therapy research and explore memory-related disorders. Dr. Shelley Berger and Penn are co-founders who hold equity, and Penn and the inventors of the optioned technology may be entitled to additional financial benefits if the technology is licensed. EpiVario is an early-stage drug discovery and development company advancing a treatment that targets the non-essential gene ACSS2 to prevent negative memory formation and reconsolidation. The company is focused on memory-related psychiatric disorders including PTSD, Alzheimer’s, and alcohol and drug addiction. Founded by University of Pennsylvania epigeneticists, EpiVario’s proof-of-concept has been established in animals and related research was published in Nature in June 2017. Led by CEO Thomas Kim, the company raised $445K in seed funding to hire additional research staff and support the first phase of preclinical research milestones. EpiVario plans to begin its Phase 1 study in 2020. The company is based in Philadelphia, PA.

Total raised

$1M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2021